drugset
drugset / Trial / NCT06423261

Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects

NCT06423261 ↗

Phase 1 Active not recruiting 100 enrolled Zhejiang Echon Biopharm Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial is conducted in China. The purpose of this clinical trial is to evaluate the safety and tolerability, pharmacokinetic (PK) characteristics, and immunogenicity of single/multiple inhalation of different doses of GB002 recombinant peptide in healthy subjects.

Timeline

Start
2023-08-24
Primary completion
2025-12-30
Completion
2026-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Seralutinib Peptide 0.625 mg Inhaled
Subject Seralutinib Peptide 1.25 mg Inhaled
Subject Seralutinib Peptide 2.5 mg Inhaled
Subject Seralutinib Peptide 5 mg Inhaled
Subject Seralutinib Peptide 6.5 mg Inhaled
Subject Seralutinib Peptide 7.5 mg Inhaled

Indications

No indication recorded.